Noora (vaccine) (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Noora (vaccine)" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

7doi.org

2^nd place

4tehrantimes.com

4,540^th place

3,354^th place

3retractionwatch.com

low place

3irct.ir

low place

1farsnews.ir

1,083^rd place

8,125^th place

1isna.ir

422^nd place

5,832^nd place

1mehrnews.com

540^th place

4,672^nd place

1iran-times.com

low place

1irannewsdaily.com

low place

1memri.org

low place

1biotechrep.ir

low place

1iranintl.com

2,247^th place

7,334^th place

biotechrep.ir

Soleymanitabar A, Gharekhanloo MA, Khalaj MP, Radfar MM, Mansour Kiaei D, Bolouriyan A, et al. (2022). "Efficacy and Adverse Effects of the Most Common COVID-19 Vaccines: a Rapid Review Study". Journal of Applied Biotechnology Reports. 9 (4): 790–798. doi:10.30491/jabr.2022.354528.1553.

doi.org

"Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial"". Journal of Medical Virology. 96 (3): e29509. March 2024. doi:10.1002/jmv.29509. PMC 11062063. PMID 38430205.
Dashti N, Golsaz-Shirazi F, Jeddi-Tehrani M, Zarnani AH, Amiri MM, Shokri F (March 2024). "Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice". Iranian Journal of Immunology. 21 (1): 1–14. doi:10.22034/iji.2024.101060.2728. PMID 38433582.
Daungsupawong H, Wiwanitkit V (May 2024). "Letter to the Editor Regarding "Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice"". Iranian Journal of Immunology. 21 (2): 184–185. doi:10.22034/iji.2024.101947.2764. PMID 38803238.
Nazarian S, Olad G, Abdolhamidi R, Motamedi MJ, Kazemi R, Kordbacheh E, et al. (September 2022). "Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models". Molecular Immunology. 149: 107–118. doi:10.1016/j.molimm.2022.06.007. PMC 9222294. PMID 35802999.
Salimian J, Ahmadi A, Amani J, Olad G, Halabian R, Saffaei A, et al. (February 2023) [2022-08-27]. "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial". Journal of Medical Virology. 95 (2): 28097. doi:10.1002/jmv.28097. PMC 9539327. PMID 36029105. (Retracted, see doi:10.1002/jmv.29509, PMID 38430205, Retraction Watch)
Soleymanitabar A, Gharekhanloo MA, Khalaj MP, Radfar MM, Mansour Kiaei D, Bolouriyan A, et al. (2022). "Efficacy and Adverse Effects of the Most Common COVID-19 Vaccines: a Rapid Review Study". Journal of Applied Biotechnology Reports. 9 (4): 790–798. doi:10.30491/jabr.2022.354528.1553.
Forthal DN (May 2023). "Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2". Journal of Medical Virology. 95 (5): e28731. doi:10.1002/jmv.28731. PMC 10618008. PMID 37212298.

farsnews.ir

"IRGC Commander: Iran-Made 'Noora' Coronavirus Vaccine Ready for 2nd Stage of Human Trial". Fars News Agency. 22 August 2021. Retrieved 30 August 2021.

iran-times.com

"Iran Covid Vaccine Report now Retracted by Journal". Iran Times. 10 May 2024. Retrieved 18 June 2024.

iranintl.com

"Virology Journal Retracts Paper On Iran-Made COVID-19 Vaccine Trials". Iran International. 3 October 2024. Retrieved 21 June 2024.

irannewsdaily.com

""Noora" vaccine successfully passing first phase of clinical trial". Iran News Daily. 27 June 2021. Retrieved 20 June 2024.

irct.ir

en.irct.ir

"IRCT | A double-blind, randomized, placebo-controlled Phase II clinical trial to evaluate the immunogenicity and safety of covid-19 recombinant RBD protein vaccine (80 microgram) of Plasma Darman Sarve Sepid Co. in healthy population". en.irct.ir. Retrieved 27 November 2021.
"IRCT |Phase 3 Clinical Trial to evaluate the Immunogenicity and Safety of Covid19 Recombinant RBD Protein Vaccine (Noora Vaccine) as a Booster Vaccine after injection of existing Vaccines in IRAN". en.irct.ir. Retrieved 23 December 2021.

irct.ir

"A randomized, double-blinded, placebo-controlled phase I clinical trial to evaluate the safety and immunogenicity of three dose regimens of COVID-19 RBD protein recombinant vaccine (AmitisGen; 80 μg and 120 μg) in a healthy population". Iranian Clinical Trials Registry. 25 June 2021. IRCT20210620051639N1. Retrieved 1 July 2021.

isna.ir

en.isna.ir

Hashemi S (27 June 2021). "Iran unveils Covid-19 vaccine "Noora"". Iranian Students' News Agency. Retrieved 18 June 2024.

mehrnews.com

en.mehrnews.com

Rahmani T (11 August 2021). "Termination of 1st phase of "Noora" vaccine clinical trial". Mehr News Agency. Retrieved 18 June 2024.

memri.org

"IRGC Commander-In-Chief General Hossein Salami At Unveiling Of The 'Noora' COVID-19 Vaccine: If The U.S. Has A Vaccine Shortage, We Are Willing To Help Them Out". MEMRI. Retrieved 21 June 2024.

nih.gov

pubmed.ncbi.nlm.nih.gov

"Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial"". Journal of Medical Virology. 96 (3): e29509. March 2024. doi:10.1002/jmv.29509. PMC 11062063. PMID 38430205.
Dashti N, Golsaz-Shirazi F, Jeddi-Tehrani M, Zarnani AH, Amiri MM, Shokri F (March 2024). "Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice". Iranian Journal of Immunology. 21 (1): 1–14. doi:10.22034/iji.2024.101060.2728. PMID 38433582.
Daungsupawong H, Wiwanitkit V (May 2024). "Letter to the Editor Regarding "Comparative Immunogenicity and Neutralization Potency of Four Approved COVID-19 Vaccines in BALB/c Mice"". Iranian Journal of Immunology. 21 (2): 184–185. doi:10.22034/iji.2024.101947.2764. PMID 38803238.
Nazarian S, Olad G, Abdolhamidi R, Motamedi MJ, Kazemi R, Kordbacheh E, et al. (September 2022). "Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models". Molecular Immunology. 149: 107–118. doi:10.1016/j.molimm.2022.06.007. PMC 9222294. PMID 35802999.
Salimian J, Ahmadi A, Amani J, Olad G, Halabian R, Saffaei A, et al. (February 2023) [2022-08-27]. "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial". Journal of Medical Virology. 95 (2): 28097. doi:10.1002/jmv.28097. PMC 9539327. PMID 36029105. (Retracted, see doi:10.1002/jmv.29509, PMID 38430205, Retraction Watch)
Forthal DN (May 2023). "Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2". Journal of Medical Virology. 95 (5): e28731. doi:10.1002/jmv.28731. PMC 10618008. PMID 37212298.

ncbi.nlm.nih.gov

"Retraction: "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial"". Journal of Medical Virology. 96 (3): e29509. March 2024. doi:10.1002/jmv.29509. PMC 11062063. PMID 38430205.
Nazarian S, Olad G, Abdolhamidi R, Motamedi MJ, Kazemi R, Kordbacheh E, et al. (September 2022). "Preclinical study of formulated recombinant nucleocapsid protein, the receptor binding domain of the spike protein, and truncated spike (S1) protein as vaccine candidates against COVID-19 in animal models". Molecular Immunology. 149: 107–118. doi:10.1016/j.molimm.2022.06.007. PMC 9222294. PMID 35802999.
Salimian J, Ahmadi A, Amani J, Olad G, Halabian R, Saffaei A, et al. (February 2023) [2022-08-27]. "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial". Journal of Medical Virology. 95 (2): 28097. doi:10.1002/jmv.28097. PMC 9539327. PMID 36029105. (Retracted, see doi:10.1002/jmv.29509, PMID 38430205, Retraction Watch)
Forthal DN (May 2023). "Comment on the immunogenicity of the Noora vaccine against SARS-CoV-2". Journal of Medical Virology. 95 (5): e28731. doi:10.1002/jmv.28731. PMC 10618008. PMID 37212298.

retractionwatch.com

Joelving F (7 March 2024). "Iran COVID-vaccine paper with 'serious flaws' retracted". Retraction Watch. Retrieved 18 June 2024.
Salimian J, Ahmadi A, Amani J, Olad G, Halabian R, Saffaei A, et al. (February 2023) [2022-08-27]. "Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial". Journal of Medical Virology. 95 (2): 28097. doi:10.1002/jmv.28097. PMC 9539327. PMID 36029105. (Retracted, see doi:10.1002/jmv.29509, PMID 38430205, Retraction Watch)
Joelving F (26 October 2023). "Publisher looking into COVID vaccine paper with 'serious flaws'". Retraction Watch. Retrieved 21 June 2024.

tehrantimes.com

"IRGC starts clinical trial of "Noora" coronavirus vaccine". Tehran Times. 27 June 2021. Retrieved 1 July 2021.
"Clinical studies of Noora vaccine published in Medical Virology". Tehran Times. 12 October 2022. Retrieved 18 June 2024.
"IRGC's "Noora" vaccine awaiting emergency use license". Tehran Times. 9 February 2022. Retrieved 19 June 2024.
""Noora" vaccine receives emergency use license". Tehran Times. 1 March 2022. Retrieved 19 June 2024.